Peptide gray market shifts to bitcoin and stablecoins

Chainalysis reported that sales by top gray‑market peptide vendors jumped 159% quarter‑over‑quarter in the first quarter of 2026, rising to $32 million from $12 million. The firm said the sector’s current pace puts the annual run rate above $100 million and that more transactions are occurring on public blockchains using bitcoin and stablecoins.

Peptides are short chains of amino acids used in legitimate research and some therapies. Chainalysis described a growing market for off‑label peptide products sold as supplements or experimental treatments. The report linked rising interest to public demand for appetite‑suppressing and cellular‑repair products following the success of GLP‑1 drugs and to online trends such as “looksmaxing” and groups focused on health and appearance.

The analysis found a concentrated group of overseas suppliers, many located in China, now supply a large share of the market. Chainalysis said banks and card processors generally prohibit sales of prescription‑grade or unregulated compounds, so sellers often operate outside traditional financial channels and offer raw, unbranded products at lower prices than pharmacies.

To handle larger volumes, vendors have adopted cryptocurrency, the report found. Chainalysis noted a shift toward stablecoins in higher‑value deposits. When the firm isolated vendors with average deposits above $1,000, the portfolio of received assets shifted to a majority of stablecoins, a pattern the report linked to attempts by vendors to reduce exposure to crypto price swings.

The expansion of on‑chain payments coincided with a decline in per‑buyer spending on independent purity testing. Chainalysis reported that, before the sales increase, wallets buying peptides from China frequently transacted with Janoshik, a chemical purity testing firm in Czechia. After the sales jump, estimated testing spend per buyer fell about 88% to roughly $8, even as Janoshik’s total testing volume rose because of the larger buyer base.

Chainalysis also identified suppliers with prior links to the market for drug precursors that have moved into peptides. The report highlighted Shanghai Sigma Audley as a firm that took in at least $1 million in bitcoin and $3.59 million in stablecoins through fentanyl precursor sales before expanding into peptides.

The report warned that many buyers appear inexperienced with both unregulated pharmaceuticals and cryptocurrency. Chainalysis said the combination of easy online purchase routes, on‑chain payments, and lower rates of independent testing creates challenges for buyers and for regulators and law enforcement.

Chainalysis attributed the payment shift in part to restrictions in traditional financial channels and to vendor strategies for managing price volatility in crypto markets.